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ABSTRACT
The objective of this study was to determine the prevalence of symptoms and problems in 
Malaysian brain pathology patients. A total of 100 respondents in Kuala Lumpur Hospital 
were included in this cross-sectional study. The study utilized European Organization for 
Research and Treatment of Cancer Quality Of Life questionnaire (EORTC QLQ-C30). 
Patient with a “symptom/problem” having the minimum response of “a little”. A response 
of “quite a bit” was defined as having a “severe symptom/problem”. The two most 
prevalent “symptoms/problems” among the neurological disorder patients were fatigue 
(65%; severe: 28%) and reduced cognitive functioning (64%; severe: 25%). The mean 
number of “symptoms/problems” ranged 
from 4.63 (meningioma) to 6.80 (cerebellar 
edema) while the mean number of “severe 
symptoms/problems” ranged from 1.39 
(astrocytic glioma) to 2.8 (cerebellar 
edema). Therefore special attention should 
be given to these patients in order to improve 
the overall quality of life of the patients.
Keywords: Brain pathology, neurological disorder, 
quality of life, severity, symptomatology
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INTRODUCTION
The cancer incidence is 3.3 per 100,000 populations among brain and other nervous system 
disorders. This consists of  male 3.6 and female 3.1 per 100,000 population in peninsular 
Malaysia (Omar et al., 2006). There are various forms of brain cancer which include 
malignant gliomas (34.6%), followed by medulloblastoma 11.3% and meningothelial 
tumours  (3.1%) of all nervous system tumours in the year 2003 till 2005 in Peninsular 
Malaysia (Lim et al., 2008).
The main aim of brain tumour management was on tumour removal while the physician 
role was to develop state free of this disease. The quality of life of patients with brain 
disorder is often neglected and it leads to the deterioration of physical, emotional, and 
social functioning (Kim et al., 2016). The cancer patients appear to have poor quality 
of life even prior to their high dose chemotherapy treatment (Larsen et al., 2003). Study 
also reported that the cancer patients with various types of diagnoses showed variation 
in ‘symptoms/problems’ which impacted on their quality of life (Johnsen et al., 2009a; 
Johnsen et al., 2009b). Moreover the patients with metastasis stage found to have weak 
physical, psychosocial and poor quality of life (Yen et al., 2006). Therefore special attention 
should be given to the patient with poor quality of life to improve their overall curability 
of the disease. 
A great deal of literature has been published from western data on other cancer 
patients (Brown et al., 2009; Costanzo et al., 2006; Distefano et al., 2008; Dodd et al., 
2010; Mehnert et al., 2009; Mystakidou et al., 2005; Okamura et al., 2002; Oozeer et al., 
2006; Reid-Arndt et al., 2009; Reimer et al., 2006; Sampogna et al., 2009; Zenger et al., 
2009). According to what we know so far, there are limited published articles concerning 
the quality of life specifically for Malaysians brain pathology patients.  Thus, the main 
aim of this study was to evaluate the quality of life in the patients with brain pathology in 
a referral centre in Malaysia. 
MATERIALS AND METHODS
The study was done at Hospital Kuala Lumpur (HKL), a referral centre for neurological 
disorder cases. All the patients who visits neurosurgery clinic between (April 2016 to 
December 2016) with neurological disorder during the sampling period and fulfilled the 
inclusion criteria were included in the study. 
The study respondents were selected following these criteria. First, the respondent 
must be with brain pathology. Second, the age of participant must be at least 18 years. 
Second, the participants should be able to well-versed in Malay, English, Mandarin or 
Tamil. Finally, the participant must be conscious and able to respond to our questionnaire.
The EORTC-QOL-30 questionnaire has been pre-tested and validated. This disease-
specific questionnaire is used to evaluate the quality of life of cancer patients. The 
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questionnaire comprised of four languages including English, Malay, Mandarin and Tamil, 
was used in the study (Aaronson et al., 1993; Mustapa and Yian, 2007). The Malay version 
had been validated among Malaysian cancer patients and it has internal consistencies for 
Global Health Status (0.91), Functional domains (0.50-0.89) and Symptoms domains (0.75-
0.99) and the sensitivity of the scale found in all the domains (Na et al., 2014).
The participants were excluded from the study if the patient wanted to withdraw from 
the study, mentally disabled, not able to be interviewed or required immediate treatment.
This study used European Organization for Research and Treatment of Cancer Quality 
Of Life (EORTC QLQ-C30) likert scale format questionnaire, version 3.0. The consent 
was obtained from the patient before the questionnaires were distributed. Information 
such as socio-demographic profiles and clinical status were assessed from the patients 
and medical records.
All the scales ranged from 1 to 4 except for the global health status scale points with the 
scale from 1 to 7 (Aaronson et al., 1993). The questionnaire was divided into functioning 
scales, symptoms scales and global health status scale. The functioning scale comprised 
physical, role, cognitive, emotional and social domains. The symptoms scale consisted of 
fatigue, pain, nausea/vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea and 
financial difficulties. The linear transformation was done referring to the EORTC scoring 
manual and all scores ranged from 0 to 100. A higher score indicates better functioning 
and good global health statuses. Conversely higher score for the symptom scale indicates 
more symptoms among the patients (Fayers et al., 2001).
The questionnaire did not have any cut-off points or defined thresholds to interpret 
functioning and symptom score as a case. Thus the percentage of frequencies of “symptoms/
problems” and the frequencies of “severe symptoms/problems” were computed by referring 
to previous study methodology. Patient with a symptom/problem having the minimum 
response of “a little” and had function scale scores ≤ 67 and symptoms scale scores ≥33. 
While a response of “quite a bit” was defined as having a “severe symptom/problem” had 
function scale scores ≤34 and symptoms scale scores ≥ 66. The explanation of this method is 
shown in Figure 1 (Johnsen et al., 2009b). The number of “symptom/problem” and “severe 
symptom/problem” answers were determined for each person ranging from 0 to 14. The 
global health status scale was removed from this method, thus leaving 14 scales in total. 
Statistical Package for Social Sciences (SPSS) program version 22.0 was used to 
analyze the data in this study. Descriptive statistics including mean, percentages and ranges 
were used to describe the sample characteristics.
Ethical clearance approval was sought from Human Research Ethics Committee, 
Universiti Sains Malaysia (USM/JEPeM/16050178) and Medical Research & Ethics 
Committee (MREC) at the Ministry of Health (MOH) (NMRR-16-1134-29874 (IIR).
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RESULTS
The study had a response rate of 93.5%. The mean age of the respondents was 45.3 years 
(95% CI= 42.6, 47.9). Tables 1 and 2 shows the socio demographic profiles and clinical 
characteristics of the respondents respectively. Patients with brain pathology with majority 
of brain tumour patients were included in the study. The neurological disorders patients in 
the Table 2 defined as patients who was shown with brain tumour in the Magnetic resonance 
imaging (MRI) report but had not been confirmed in the biopsy results. The majority of 
the patients underwent surgery.
Figure 1. Illustration of the definition of ‘symptom/problem’ and ‘severe symptom/problem’ 
Source: Johnsen et al., 2009b
Table 1
Socio-demographic characteristics of neurological disorder respondents in HKL (n=100)
Characteristics n Percentage %)
Age (year)
18-20 2 2.0
21-30 15 15.0
31-40 21 21.0
41-50 25 25.0
51-60 21 21.0
61-70 15 15.0
71 1 1.0
Gender
Female 66 66.0
Male 34 34.0
Ethnicity
Malay 78 78.0
Chinese 12 12.0
Indian 9 9.0
Others 1 1.0
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Table 1 (continue)
Characteristics n Percentage %)
Religion
Muslim 78 78.0
Buddhist 11 11.0
Hindu 7 7.0
Christian 3 3.0
Others 1 1.0
Marital status
Single 24 24.0
Married 74 74.0
Widowed 1 1.0
Divorced 1 1.0
Children
Yes 68 68.0
No 32 32.0
Highest level of formal education
Primary 13 13.0
Secondary 48 48.0
College/University 38 38.0
No education 1 1.0
Highest certificate
Primary School Evaluation Test (UPSR/PSET) 12 12.0
Lower Certificate of Education (PMR/SRP/LCE) 14 14.0
Malaysian Certificate of Education (SPM/SPMV/MCE) 29 29.0
Malaysian Higher School Certificate (STPM/HSC) 3 3.0
Certificate/Diploma 20 20.0
Degree 18 18.0
Master 3 3.0
No education 1 1.0
Occupation status
Working 55 55.0
Not working 45 45.0
Working sector 
Government 21 21.0
Non government 31 31.0
Self employment 1 1.0
Not working
Semi goverment
45
2
45.0
2.0
Total monthly income household (RM ) 
0-3000 53 53.0
3001-6000 13 13.0
6001-9000 8 8.0
>9001
others
4
22
4.0
22.0
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Table 2
Clinical characteristic of brain disorder respondents in HKL
Characteristics n Percentage (%)
Year of diagnosis (n=92)
2015-2016 34 34.0
2013-2014 17 17.0
2011-2012
2009-2010
2007-2008
2005-2006
<2005
11
6
7
3
14
11.0
6.0
7.0
3.0
14.0
Neurological disorders (n=100)
Astrocytic glioma 13 13.0
Meningioma 19 19.0
Pituitary adenoma 15 15.0
Carvenoma 7 7.0
Schwanoma 5 5.0
Craniopharyngioma 3 3.0
Ethmoid 1 1.0
Frontal lobe tumour 1 1.0
Fibrosarcoma 1 1.0
Cerebellar edema 4 4.0
Germinoma 1 1.0
Hemorragic brain 3 3.0
Metastatic carcinoma 1 1.0
Brain lession 2 2.0
Mucopyocele 1 1.0
Aneurysm 1 1.0
Hydrocephalus 3 3.0
Unclassified neurological disorders 19 19.0
Treatment(n=70)
Pharmacological medication group 27 27.0
Surgery group 38 38.0
Radiotherapy group 6 6.0
Table 3 shows the mean score of five multi-item function scales. The most severe 
impairment in functioning was the cognitive functioning (mean score=61). The cut-off 
value, indicates that 63% of brain pathology patients had impairment in their cognitive 
functioning (severity= 25%). Another leading symptom and problem among the patients 
was fatigue (severity=28%) which affected 65% of the patients. 
Thirty-six percent of the patients had impairment in their physical functioning 
(severity=5%), followed 44% of the patients with impaired role functioning (severity=2%). 
Social functioning was impaired in 26% of patients (severity= 9%). In the symptoms 
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counterparts, the most severe symptom was fatigue (mean score =44.89), followed 
by financial difficulties (mean score=34), insomnia (mean score=29.67), pain (mean 
score=29.33), appetite loss (mean score=17), constipation (mean score=12.67), nausea 
and vomiting (mean score=11.67), dyspnea (mean score=10) and diarrhea (mean 
score=4.67). Using the cut-off values, 65% of the patients had fatigue (severity 28%), 
51% had financial difficulties (severity=30%), 47% had pain (severity=20%), 43% had 
insomnia (severity=29%), 26% had appetite loss (severity=16%), 24% had constipation 
(severity=10%), 15% had nausea and vomiting (severity=7%), 20% had dyspnea 
(severity=9%) and 12% had diarrhea (severity=1%). 
In the study, the mean number of “symptoms/problems” was 5.22 while the mean 
number of “severe symptoms/problems” was 2.10. Overall, the cerebellar edema patients 
had the most symptoms and problems with a mean number of 6.80. The mean number of 
“symptoms/problems” ranged from 4.63 (meningioma) to 6.80 (cerebellar edema); the 
mean number of “severe symptoms/problems” ranged from 1.39 (astrocytic glioma) to 
2.8 (cerebellar edema). Most shockingly, the study found 90% of the patients had at least 
one “symptom/problem”.
DISCUSSION
The present study was aimed to determine the symptoms and problems affecting the quality 
of life of brain pathology patients. The study showed that the symptoms and problems 
were frequent among the patients. The cut-off value, indicates that 63% of the patients 
had impairment in cognitive functioning (severity = 25%). This finding is in agreement 
with previous case control studies, which found the patients with brain tumour had more 
cognitive impairment compared to healthy patients. The study not only demonstrated that 
the patients suffered more in cognitive impairment compared to healthy adults but the 
cognitive functioning worsened after the surgery (Zarghi, 2014). In the previous study 
among Malaysians with primary intracranial tumor, a small number of patients (n=38) was 
included in the analyses.  The patients were identified with reduced cognitive functioning, 
emotional functioning and global health status before the surgery compared to after the 
surgery. The patients also tended to have more fatigue and pain symptoms before the 
surgery (Ooi & Mazlina, 2013).
In the current study also found the most severe symptom was fatigue which had the 
highest mean score followed by financial difficulties, insomnia and pain. This defined 65% 
of the patients had fatigue (severity=28%), financial difficulties (51%; severity: 30%), 
pain (47; severity=20) and insomnia (43%; severity=29%). The current study found 90% 
of all brain pathology patients having at least one “symptoms/ problems”. Similarly in a 
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study done by Johnsen et al (2009a) also reported that the cancer patients had higher mean 
scores on the symptom scale and experienced fatigue followed by pain and insomnia. 
Comparing the cancer patients in each domain, fatigue (55%), reduced role functioning 
(49%), insomnia (46%), pain (37%) and dyspnoea (36%) were identified in the study. 
The study found 82% of all cancer patients fulfilled the criteria of at least one ‘symptoms/
problems’ in their quality of life. The functional scale of role and physical functioning 
were found to be severely impaired in the patients (Johnsen et al., 2009b). The patients 
with reduced global quality of life found to have poor physical, cognitive, social and role 
functioning and more appetite loss and financial difficulties (Kim et al., 2016). In another 
study it was shown the patients had elevated symptoms of  fatigue, pain, sleep disturbance 
and depression and reported poor functional status and low quality of life (Dodd et al., 
2010). The patients who were appeared to be more fearful of their disease relapse had much 
more reduced quality of life, specifically in their fatigue, financial difficulties, emotional 
functioning, and appetite domains (Franssen et al., 2009).
The cancer patients treatment modalities also lead to  increased level of fatigue, poor 
appetite and physical functioning and reduced quality of life (Johnsen et al., 2009b). At the 
pre and post operative stage, the patients are mostly effected in their emotional functioning 
and dyspnea symptoms. The patients also having more symptoms of fatigue before the 
surgery (Kim et al., 2016). Therefore it is becoming increasingly difficult to ignore the 
patient’s poor quality of life and more attention needs to be given together with supportive 
care in order to improve the overall curability of the patients (Ernstmann et al., 2009).
CONCLUSION
The study proved that the patients with brain pathology in referral centre in Malaysia 
caused significant impairment in the quality of life. The fatigue and reduced cognitive 
functioning were two leading symptoms and problems among the patients. There is a 
significant improvement in cancer management, however the overall treatment will remain 
poor if medical personnel does not apply a balanced pharmacotherapy and psychotherapy 
management in order to improve the patients’ quality of life.
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